BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 18675959)

  • 1. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.
    Badawy A; Elnashar A; El-Ashry M; Shahat M
    Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Questioning GnRH analogs for gonadal protection in cancer patients.
    Oktay K; Sönmezer M
    Fertil Steril; 2009 Aug; 92(2):e32; author reply e34. PubMed ID: 19646599
    [No Abstract]   [Full Text] [Related]  

  • 3. GnRH analogue for chemotherapy-induced ovarian damage: too early to say?
    Peccatori F; Demeestere I
    Fertil Steril; 2009 Aug; 92(2):e33; author reply e34. PubMed ID: 19646600
    [No Abstract]   [Full Text] [Related]  

  • 4. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
    Choi MC; Chung YS; Lee JW; Kwon BS; Park BK; Kim SI; Shim SH; Lee KB; Seong SJ; Lee SJ; Lee SH; Yoo HJ; Song T; Kim MK; Baek MH; Kang S; Kim YM
    Eur J Cancer; 2020 Jul; 133():56-65. PubMed ID: 32442924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
    Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
    JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
    Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
    J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
    Leonard RCF; Adamson DJA; Bertelli G; Mansi J; Yellowlees A; Dunlop J; Thomas GA; Coleman RE; Anderson RA;
    Ann Oncol; 2017 Aug; 28(8):1811-1816. PubMed ID: 28472240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.
    Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas RO; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
    J Clin Oncol; 2013 Mar; 31(7):903-9. PubMed ID: 23129737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.
    Senra JC; Roque M; Talim MCT; Reis FM; Tavares RLC
    Ultrasound Obstet Gynecol; 2018 Jan; 51(1):77-86. PubMed ID: 29055060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy.
    Blumenfeld Z; Avivi I; Linn S; Epelbaum R; Ben-Shahar M; Haim N
    Hum Reprod; 1996 Aug; 11(8):1620-6. PubMed ID: 8921104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
    Chen H; Xiao L; Li J; Cui L; Huang W
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic treatment with a gonadotrophin-releasing hormone agonist on peripheral concentrations of FSH and LH, and ovarian function in heifers.
    Gong JG; Bramley TA; Gutierrez CG; Peters AR; Webb R
    J Reprod Fertil; 1995 Nov; 105(2):263-70. PubMed ID: 8568770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers.
    Reh A; Oktem O; Oktay K
    Fertil Steril; 2008 Nov; 90(5):1635-9. PubMed ID: 18166178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
    Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ
    Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
    Moore HC; Unger JM; Phillips KA; Boyle F; Hitre E; Porter D; Francis PA; Goldstein LJ; Gomez HL; Vallejos CS; Partridge AH; Dakhil SR; Garcia AA; Gralow J; Lombard JM; Forbes JF; Martino S; Barlow WE; Fabian CJ; Minasian L; Meyskens FL; Gelber RD; Hortobagyi GN; Albain KS;
    N Engl J Med; 2015 Mar; 372(10):923-32. PubMed ID: 25738668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian rescue/protection from chemotherapeutic agents.
    Blumenfeld Z
    J Soc Gynecol Investig; 2001; 8(1 Suppl Proceedings):S60-4. PubMed ID: 11223377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
    Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
    Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
    Blumenfeld Z; Zur H; Dann EJ
    Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report.
    Kim HJ; Noh WC; Nam SJ; Park BW; Lee ES; Im SA; Jung YS; Yoon JH; Kang SS; Park KH; Lee SJ; Jeong J; Lee MH; Cho SH; Kim SY; Kim HA; Han SH; Han W; Hur MH; Kim S; Ahn SH
    Eur J Cancer; 2021 Jul; 151():190-200. PubMed ID: 34010788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.